Primary resistance to osimertinib despite acquired T790M

Current National Comprehensive Cancer Network (NCCN) guidelines suggest plasma‐based testing (liquid biopsy) for T790M in epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung carcinoma (NSCLC) with acquired resistance to first‐/second‐generation EGFR tyrosine kinase inhibitors (TKIs)....

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Ling‐Kai, Chang, Yih‐Leong, Shih, Jin‐Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002899/
https://www.ncbi.nlm.nih.gov/pubmed/32042433
http://dx.doi.org/10.1002/rcr2.532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002899/
https://www.ncbi.nlm.nih.gov/pubmed/32042433
http://dx.doi.org/10.1002/rcr2.532

Ejemplares similares